Omada Health

OMDA on Nasdaq. Omada sells virtual health care programs to employers and health plans. Market value $1.3bn.

Watch this stockFree. We tell you when something changes.

Price checks use the past 12 months to June 2026. Quality checks use five annual reports, the latest for the year to December 2025.

Should I look at this?

Look carefully before going further

Read the warning sign in its own filings

This is not advice. Check the numbers below.

Compare with another stock

Cash yield
past 12 months to June 2026
1.3%low

For every $100 of what the whole company costs, it produced $1.35 of spare cash in the past 12 months. A savings account pays about $4.

Price to profit
past 12 months to June 2026
n/a

The filings do not give us enough to work this out.

Return on capital
five annual reports to December 2025
n/a

The filings do not give us enough to work this out.

Quality score: not known. Price score: 9 of 100. Our list needs 70 on quality and 60 on price.

$20.73 a share, 102% above its 1-year low

Over the past year the price has ranged from $10.28 to $26.92.

Pays no dividend

Prices from Tuesday’s close (6 October).

Five years of cash, in billions

0.0
0.0
202512 monthsto Jun '26
Revenue
$260m
Operating margin
-4.6%
Debt to equity
0.00
Shares outstanding
0.06bn

Health checks

  • Free cash flow positive1 of 1 years
  • Accounting looks honest (Beneish)Not enough data
  • Financial strength (Piotroski)Not enough data
  • Profit backed by cash (accruals)Not enough data
  • Debt0.00× equity
  • Revenue growth, five yearsUnknown
  • Buying back its own sharesRoughly flat

The quarter to June 2026

How the business did, compared with the same quarter a year earlier.

  • Sales: $88 million last quarter, up 43% on a year ago.
  • Profit: $5 million, after a loss of $5 million a year ago.
  • 191% more shares than a year ago. Each share owns a bit less of the company.
Sales by quarter
Sales by quarter
Quarter toAmount
June 2025$61m
September 2025$68m
December 2025$76m
March 2026$78m
June 2026$88m
Profit by quarter
Profit by quarter
Quarter toAmount
June 2025-$5m
September 2025-$3m
December 2025$5m
March 2026-$3m
June 2026$5m

From the company's quarterly reports to the SEC.

Dates

Next results (estimated)
n/a
Last annual report (10-K)
6 March 2026
Next quarterly (estimated, 10-Q)
6 November 2026

Who owns it

None of the long-term investors we follow own it. 154 funds in all.

Jun '25
Dec '25
Jun '26
Largest holders overall

From 13F filings for the quarter ended 30 June 2026.

Big holders and activists

6 investors own more than 5%.

  • Michael Boggs
    Passive investor
    at least 9.1%
    (filed with 7 related holders)
    Since 30 June 2025
  • at least 6.3%−3.6 pts
    (filed with 4 related holders)
    Since 30 June 2026
  • American Century Investment Management, Inc.
    Passive investor
    at least 6.2%
    (filed with 2 related holders)
    Since 30 June 2026
  • The Cigna Group
    Passive investor
    at least 5.8%
    (filed with 1 related holder)
    Since 30 June 2025
  • FMR LLC
    Passive investor
    at least 5.6%−2.9 pts
    (filed with 1 related holder)
    Since 31 March 2026
  • Benjamin A. Horowitz
    Passive investor
    at least 4.2%−1.9 pts
    (filed with 5 related holders)
    Since 31 March 2026
  • Casey M Tansey
    Passive investor
    Sold down below 5%
    Since 31 December 2025

From Schedule 13D and 13G filings: anyone owning more than 5% must file one.

What insiders did

No insider bought shares on the open market in the last 12 months. 4 sold $12m, $8m of it under preset trading plans.

  • Duffy Sean P.
    Chief Executive Officer, Director
    Sold
    under a preset trading plan
    Date
    1 October 2026
    Shares
    17,258
    Price
    $20.68
    Value
    $356,915
  • Duffy Sean P.
    Chief Executive Officer, Director
    Sold
    under a preset trading plan
    Date
    10 September 2026
    Shares
    14,960
    Price
    $21.87
    Value
    $327,197
  • Cook Steven L.
    Chief Financial Officer
    Sold
    under a preset trading plan
    Date
    10 September 2026
    Shares
    6,800
    Price
    $21.86
    Value
    $148,640
  • Shao Wei-Li
    President
    Sold
    under a preset trading plan
    Date
    10 September 2026
    Shares
    4,036
    Price
    $21.85
    Value
    $88,206
  • Gracey Craig
    Chief Accounting Officer
    Sold
    under a preset trading plan
    Date
    9 September 2026
    Shares
    644
    Price
    $21.73
    Value
    $13,995
  • Duffy Sean P.
    Chief Executive Officer, Director
    Sold
    under a preset trading plan
    Date
    1 September 2026
    Shares
    21,572
    Price
    $23.62
    Value
    $509,465
  • Cook Steven L.
    Chief Financial Officer
    Sold
    under a preset trading plan
    Date
    27 August 2026
    Shares
    1,108
    Price
    $25.00
    Value
    $27,700
  • Shao Wei-Li
    President
    Sold
    under a preset trading plan
    Date
    12 August 2026
    Shares
    9,418
    Price
    $25.02
    Value
    $235,607
  • Cook Steven L.
    Chief Financial Officer
    Sold
    under a preset trading plan
    Date
    11 August 2026
    Shares
    1,607
    Price
    $25.01
    Value
    $40,197
  • Cook Steven L.
    Chief Financial Officer
    Sold
    under a preset trading plan
    Date
    10 August 2026
    Shares
    15,235
    Price
    $25.03
    Value
    $381,350

From Form 4 filings: insiders must report trades in their own company's shares within two days.

Warning signs in its filings

Problems the company itself reported to the SEC, in its own words.

1 serious warning sign in Omada Health’s filings.

We look for five warning signs: doubt it can keep going, weak checks on its own accounts, a notice that its past accounts can't be relied on, a change of auditor, and one customer bringing in a big share of sales. We don't check lawsuits, investigations or debt yet.

We checked the auditor's report, internal controls, restatement notices, auditor changes and big customers in the 10-K filed 6 Mar 2026, plus the 10-Q filed 7 Aug 2026 and 3 later 8-Ks.

  • Weak checks on its own accounts

    Serious

    The company said its checks on its own accounts did not work at the end of its latest quarter. Mistakes could slip into the numbers.

    “Based on that evaluation, our principal executive officer and principal financial officer concluded that, as of June 30, 2026, our disclosure controls and procedures were not effective at the reasonable assurance level because of the material weakness in our internal control over financial reporting described below.”
    Show the full paragraph
    Our management, with the participation of our principal executive officer and principal financial officer, evaluated the effectiveness of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934 (the “Exchange Act”), as of the end of the period covered by this Quarterly Report on Form 10-Q. Based on that evaluation, our principal executive officer and principal financial officer concluded that, as of June 30, 2026, our disclosure controls and procedures were not effective at the reasonable assurance level because of the material weakness in our internal control over financial reporting described below.

    From the 10-Q filed 7 August 2026, Part I, Item 4. Controls and Procedures. Read it in the filing

  • One big customer

    Worth knowing

    One customer brings in a big share of sales: 33% last year. Losing that customer would hurt.

    “For the year ended December 31, 2025, we had one health plan or PBM that accounted for 32% of our revenue, and a second health plan or PBM that accounted for 33% of our revenue.”

    From the 10-K filed 6 March 2026, Item 1A. Risk Factors. Read it in the filing

A 10-K is the yearly report every US company files with the SEC. An 8-K is a short notice of a big event.

What could go wrong

Cheap for a reason is the question the numbers cannot answer.

Whether the price already reflects the risks is what the deep dive is for.

The deep dive

Everything above is arithmetic on public filings. The deep dive reads the last ten years of annual reports, the proxy statements, and the earnings calls, then argues the case the way Buffett, Klarman, and Hohn would, and checks every claim against the source.

  • What the business is worth, as a range, and the margin of safety at today’s price
  • Prices to start buying, buy, and buy hard
  • The three things that would make this a mistake
  • Every number footnoted to the filing it came from
Create a free account to run it

Your first deep dive is free.

What a finished deep dive looks like

Not advice. Numbers on this page come from SEC filings and are updated each night; prices are updated again after the US market closes. The five-year figures are rounded.